Dishman Carbogen Amcis
NSE: DCAL · ISIN INE385W01011 · Healthcare
₹168.50+6.32 (+3.90%)
Monday 9 November, 12:04 IST. Delayed. Source: Yahoo Finance.
Price chart
₹168.50 +6.32 (+3.90%) today
The day
- Previous close
- ₹162.18
- Open
- ₹162.19
- Day high
- ₹173.98
- Day low
- ₹162.00
Listed on NSE since 21 September 2017.
Key numbers
- Market value
- ₹2,455.85 Cr
- P/E (trailing)
- 152.08
- EPS (trailing)
- ₹1.03
- Price to book
- 0.37
- Dividend yield
- 0.00%
- Debt to equity
- 0.46
- Profit margin
- 0.6%
- Beta
- 0.72
- Volume today
- 6.97 L
- Average volume
- 2.62 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹2,315.05 Cr | ₹-29.80 Cr |
| FY24 | ₹2,543.62 Cr | ₹-153.45 Cr |
| FY25 | ₹2,642.08 Cr | ₹3.24 Cr |
| FY26 | ₹2,878.12 Cr | ₹97.45 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹678 Cr | ₹-58 Cr | −347.2% |
| Q4 FY26Jan–Mar 2026Audited | ₹851 Cr | ₹22 Cr | −49.5% |
| Q3 FY26Oct–Dec 2025 | ₹720 Cr | ₹-13 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹653 Cr | ₹65 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹708 Cr | ₹23 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹716 Cr | ₹43 Cr | – |
Source: Dishman Carbogen Amcis’s results filed with NSE, consolidated (the whole group). Net profit is the share of Dishman Carbogen Amcis’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹3,217 Cr | ₹3,147 Cr |
| Investments | ₹91 Cr | ₹91 Cr |
| Inventories | ₹1,019 Cr | ₹1,028 Cr |
| Owed by customers | ₹673 Cr | ₹655 Cr |
| Cash and equivalents | ₹788 Cr | ₹464 Cr |
| Total assets | ₹11,923 Cr | ₹11,109 Cr |
| Borrowings | ₹2,775 Cr | ₹2,244 Cr |
| Total liabilities | ₹5,246 Cr | ₹4,744 Cr |
| Shareholders’ equity | ₹6,677 Cr | ₹6,365 Cr |
Source: Dishman Carbogen Amcis’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Dishman Carbogen Amcis
Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes; ammonium and phosphonium; quats, phosphoranes, and wittig reagents; generic intermediates; cholesterol and lanolin-related products; sterile injectables; specialty chemicals and disinfectants, as well as hand and body wash, sanitizers, and antiseptic formulations. It also provides encapsulation and formulation capabilities; phase transfer catalysts; drug product, finished, and HiPo formulations; generic and highpotent APIs; Health and personal care solutions; and drug linkers and payloads. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
- Industry
- Biotechnology
- Based in
- Ahmedabad
- Employees
- 934
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Dishman Carbogen Amcis in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 0.20 Per Share
Dividend · ex-date 12 September 2019
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.